George D. Yancopoulos, MD, PhD, is Regeneron’s Founding Scientist, President, and Chief Scientific Officer. Dr. Yancopoulos received his MD and PhD from Columbia University and was Dr. Fred Alt's first post-doc, working in molecular immunology. Dr. Yancopoulos pursued a career in academia until he met his Regeneron co-founder, Leonard Schleifer, MD, PhD, in the late 1980s and saw the potential to make a major impact on medicine through biotechnology.
Regeneron is now a leading biopharma company with more than 7,000 employees and facilities in the US, Ireland, and the UK. With a robust research and development engine and an unwavering commitment to its science-driven approach, Regeneron has produced seven FDA-approved medicines for patients with serious diseases, including: cancer, vision-threatening eye diseases, atopic dermatitis, and rheumatoid arthritis.
Dr. Yancopoulos and his team have built a robust pipeline of investigational treatments, driven by Regeneron's foundational technologies for target discovery and drug development, such as the VelociGene® and VelocImmune® platforms. Regeneron is committed to continual innovations in R&D, such as through the Regeneron Genetics Center, a world-leading human genetics effort that has already sequenced exomes from over 300,000 people.
Dr. Yancopoulos is deeply committed to inspiring top talent to pursue scientific careers through STEM education programs. He plays an active role in Regeneron's STEM commitments, including the Regeneron Science Talent Search, the nation’s oldest and most prestigious high school science competition, formerly sponsored by Westinghouse and Intel.